Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2003-10-22
2010-02-23
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S155100, C424S141100
Reexamination Certificate
active
07666412
ABSTRACT:
The present invention relates to methods for the diagnosis, evaluation and treatment of metastatic diseases using metastatic sequences, such as caveolin, to target metastatic cells. According to the methods of the present invention, certain cancers, including metastatic prostate cancer, may be treated by therapies which suppress expression of the caveolin gene. The present invention relates to biological technologies designed to block the activity of caveolin or the function of caveolae, including vector delivery of antisense caveolin sequences, the use of anti-caveolin antibodies, the use of promoters, and other approaches targeting the expression of caveolin.
REFERENCES:
patent: 4317818 (1982-03-01), Benson et al.
patent: 4925835 (1990-05-01), Heston
patent: 5116615 (1992-05-01), Gokcen et al.
patent: 5260224 (1993-11-01), Stossel et al.
patent: 5633161 (1997-05-01), Shyjan
patent: 5783182 (1998-07-01), Thompson
patent: 5834234 (1998-11-01), Gallo
patent: WO 86/03226 (1986-06-01), None
patent: WO 94/04196 (1994-03-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 94/28129 (1994-12-01), None
patent: WO 95/19369 (1995-07-01), None
patent: WO 96/30389 (1996-10-01), None
patent: WO 97/09055 (1997-03-01), None
patent: WO 97/18454 (1997-05-01), None
patent: WO 99/22773 (1999-05-01), None
Jain R. K. Scientific American, 271(1): 58-65, Jul. 1994.
Dillman R. O., Annals of Internal Medicine, 111:592-603, 1989.
Weiner L. M. Seminars in Oncology, 26 (4 Suppl 12): 41-50, Aug. 1999.
Dillman, R. O. Journal of Clinical Oncology, 12(7):1497-1515, 1994.
Nelson, J. B. Nature Medicine, 4:1011-1012, 1998.
Lee et al., Oncogene, vol. 16, p. 1391-1397, 1998.
Yang et al Clinical Cancer Research vol. 4, p. 1873-80, Aug. 1998. IDS: HHH.
Meredith et al Prostate Carcinoma Radioimmunotherapy, vol. 35 p. 1017-1022. 1994.
Goethuys et al. Am J Clin Oncol. vol. 20, p. 40-5, 1997.
Nasu et al. Nat Med, vol. 4, p. 1062-3, Sep. 1998.
Welch, Danny R., et al. “Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential”,Proc. Natl. Acad. Sci. USA,vol. 87, pp. 7678-7682. Oct. 1990.
Thompson, Timothy C., et al. “Multistage Carcinogenesis Induced byrasandmycOncogenes in a Reconstituted Organ”,Cell,vol. 56, pp. 917-930. Mar. 24, 1989.
Fingert et al., “In vivo model for differentiation therapy of leukemia and solid tumors.”National Institutes of Health Publication,84-2635, Serno Symposia Publications from Rven. Press, pp. 277-286 (1984).
Taber's Cyclopedic Medical Dictionary, F.A. David Company, Philadelphia, PA, edited by Vardara et al. (1993).
Liang, Peng, et al., “Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells”,Cancer Research,52, pp. 6966-6968. Dec. 15, 1992.
Merz, et al. “Elevated Transforming Growth Factor-β1 and β3 mRNA Levels are Associated with ras+myc-Induced Carcinomas in Reconstituted Mouse Prostate: Evidenced for a Paracrine Role during Progression”.Molecular Endocrinology,vol. 5, No. 4, (1991) pp. 503-513.
Poster Session Abstracts: First SPORE Investigators' Meeting, “The Role of Retinoids in Prostate Cancer Chemoprevention” Jul. 18-20, 1993, p. 30.
Slawin, et al. “Dietary Fenretinide, a Synthetic Retinoid, Decreases the Tumor Incidence and the Tumor Mass of ras+myc-induced Carcinomas in the Mouse Prostate Reconsititution Model System”,Cancer Research,vol. 53, pp. 4461-4465, Oct. 1, 1993.
Thompson, et al. “Transgenic Models for the Study of Prostate Cancer”, (Supplement)Cancer,vol. 71, No. 3, Feb. 1, 1993, pp. 1165-1171.
Donehower, et al. “Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours”,Articles,Nature, vol. 356, Mar. 19, 1992, pp. 215-221.
Thompson, et al.,“Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer”,Oncogene(1995) vol. 10, pp. 869-879.
Macoska, et al. “Loss of the 17p Chromosomal Region in a Metastatic Carcinoma of the Prostate”,The Journal of Urology,vol. 147, Apr. 1992, pp. 1142-1146.
Taylor, et al. “Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination”,Oncogene,Feb. 10, 1992, pp. 1383-1390.
Hall, et al. “Adenylate Kinase: An Oncodevelopmental Marker in an Animal Model for Human Prostatic Cancer”,Clinical Chemistry,vol. 31, No. 10, (1985), pp. 1689-1691.
Thompson, et al., Multistage Carcinogenesis Induced by ras and myc Oncogenes in a Reconstituted Organ,Cell,vol. 56, pp. 917-930, Mar. 24, 1989.
Slawin, et al., American Urological Association, Inc., Annual Meeting—San Antonio, Oct. 1, 1992, Dietary Retinoids Decrease the Incidence and Increase Lymphocytic Infiltration of ras+myc Induced Carcinomas in the Mouse Prostate Reconstitution Model System.
Thompson, et al.. “Transforming Growth Factor β1 as a Biomarker for Prostate Cancer”,Journal of Cellular Biochemistry,Supplement 16H: pp. 54-61 (1992).
Thompson et al. “Genetic Predisposition and Mesenchymal-Epithelial Interactions in ras+myc-Induced Carcinogenesis in Reconstituted Mouse Prostate”Molecular Carcinogenesis,vol. 7, pp. 165-179 (1993).
Bookstein et al. “p53 Is Mutated in a Subset of Advanced-Stage Prostate Cancer1”,Cancer,vol. 53, pp. 3369-3373, Jul. 19, 1993.
Carter, et al. “Prediction of Metastatic Potential in an Animal Model of Prostate Cancer: Flow Cytometric Quantification of Cell Surface Charge”,The Journal of Urology,vol. 142, pp. 1338-1341, Nov. 1989.
Fox, et al. “p53 And c-myc Expression in Stage A1 Prostatic Adenocarcinoma: Useful Prognostic Determinants?”The Journal of Urology,vol. 150, pp. 490-494, Aug. 1993.
Einstein, “Hormonal Therapy for Prostate Cancer—When to Use it”,Cancer Control,Jan./Feb. 1995, pp. 32-36.
Thompson, et al., “Loss of p53 Function Leads to Metastasis in ras+myc-Initiated Mouse Prostate Cancer”, Abstract for Fogarty International Meeting, Jun. 26-28, 1995.
Xiong, et al. “Human D-Type Cyclin,”Cell,vol. 65: pp. 691-699 (May 17, 1991).
Manam, et al., “Dose related changes in the profile of ras mutations in chemically induced CD-1 mouse liver tumors,”Carcinogenesis,vol. 16(5)pp. 1113-1119 (May 1995).
Blok, et al., “Isolation of cDNA's that are differentially expressed between antrogen-dependent and androgen independent prostate carcinoma cells using differential display PCR.”Prostate,vol. 26(4), pp. 213-224 (Apr. 1995).
Wu, et al. “Identification of a human hepatocellular carcinoma-associated tumor suppressor gene by differential display polymerase chain reaction,”Life Sciences,vol. 57(11), pp. 1077-1085 (Nov. 1995).
Schneider, et al. “7,12-Dimethylben[a] anthracene-Induced Mouse Keratinocyte Malignant Transformation Independent of Harvey ras Activation,”J. of Investigative Dermatology,vol. 101(4), pp. 595-599 (Oct. 1993).
Neumann, H.G., “entstehung und Behandlung von Turoren, Immnunosupressiva”,Allgemeine und Specielle Pharmakologie and Toxikologie,Edition 5. 1987.
Schlag P.M., “Fruherkennung von Krebs mit Hilfe von molekulariologischen Markem”,Onkologie,18, pp. 207, 1995.
Truong, et al. “Association of Transforming Growth Factor-β1with Prostate Cancer: An Immunohistochemical Study,”Human Pathology,vol. 24, No. 1, pp. 4-9 (Jan. 1993).
Aihara, et al., “Frequency of Apoptotic Bodies Positively Correlates with Gleanson Grade in Prostate Cancer,”Human Pathology,vol. 25, No. 8, pp. 797-801 (Aug. 1994).
Egawa, et al., “Alterations in mRNA levels for Growth-Related Genes after Transplantation into Castrated Hosts in Oncogene-Induced Clonal Mouse Prostate Carcinoma,”Molecular Carcinogenesis,vol. 5, pp. 52-61 (1992).
Glenney, “Tyrosine Phosphorylation of a 22-kDa Protein is Correlated with Tr
Baylor College of Medicine
Helms Larry R.
Vinson & Elkins LLP
Yao Lei
LandOfFree
Methods for the treatment of neoplastic disorders with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of neoplastic disorders with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of neoplastic disorders with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4170823